- Home
- LBTYA vs RYTM Comparison
LBTYA vs RYTM Comparison
Compare LBTYA & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBTYA
- RYTM
- Stock Information
- Founded
- LBTYA 2004
- RYTM 2008
- Country
- LBTYA Bermuda
- RYTM United States
- Employees
- LBTYA N/A
- RYTM N/A
- Industry
- LBTYA Cable & Other Pay Television Services
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- LBTYA Telecommunications
- RYTM Health Care
- Exchange
- LBTYA Nasdaq
- RYTM Nasdaq
- Market Cap
- LBTYA 3.6B
- RYTM 4.3B
- IPO Year
- LBTYA N/A
- RYTM 2017
- Fundamental
- Price
- LBTYA $9.81
- RYTM $61.09
- Analyst Decision
- LBTYA Buy
- RYTM Strong Buy
- Analyst Count
- LBTYA 5
- RYTM 12
- Target Price
- LBTYA $15.92
- RYTM $76.75
- AVG Volume (30 Days)
- LBTYA 2.1M
- RYTM 527.2K
- Earning Date
- LBTYA 07-24-2025
- RYTM 08-05-2025
- Dividend Yield
- LBTYA N/A
- RYTM N/A
- EPS Growth
- LBTYA N/A
- RYTM N/A
- EPS
- LBTYA N/A
- RYTM N/A
- Revenue
- LBTYA $4,421,800,000.00
- RYTM $136,863,000.00
- Revenue This Year
- LBTYA $8.29
- RYTM $37.56
- Revenue Next Year
- LBTYA $0.74
- RYTM $74.99
- P/E Ratio
- LBTYA N/A
- RYTM N/A
- Revenue Growth
- LBTYA 32.44
- RYTM 48.88
- 52 Week Low
- LBTYA $9.03
- RYTM $39.46
- 52 Week High
- LBTYA $21.56
- RYTM $69.89
- Technical
- Relative Strength Index (RSI)
- LBTYA 48.60
- RYTM 45.46
- Support Level
- LBTYA $9.62
- RYTM $60.70
- Resistance Level
- LBTYA $10.01
- RYTM $62.65
- Average True Range (ATR)
- LBTYA 0.24
- RYTM 2.36
- MACD
- LBTYA 0.03
- RYTM -0.57
- Stochastic Oscillator
- LBTYA 49.24
- RYTM 5.93
About LBTYA Liberty Global Ltd.
Liberty Global is a holding company with interests in several telecom companies in the UK, the Netherlands, Belgium, Switzerland, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies, and has pursued a strategy since 2016 to merge or partner with mobile-network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.